Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01617161|
Recruitment Status : Active, not recruiting
First Posted : June 12, 2012
Last Update Posted : August 24, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
We are studying whether men being treated for prostate cancer have the same amount of side effects from either one of two different external radiation treatments: IMRT or PBT. With IMRT, a number of x-ray beams are used to shape the radiation to the prostate. PBT is another type of external radiation treatment for prostate cancer that is used in a few centers in the United States. Protons are tiny particles with positive charge that can be controlled to travel a certain distance and stop. PBT is precise like IMRT, but it uses proton beams instead of x-ray beams.
IMRT and PBT aim to deliver most of the radiation to the prostate cancer while sparing surrounding tissues. Both IMRT and PBT have been used in the treatment of prostate cancer and are thought to be equally effective at curing prostate cancer. However, both treatments have also been shown to cause the potential side effects of radiation, including bowel, urinary and erectile problems. It is possible that side effect rates with PBT will be lower, the same, or even higher than with IMRT, but this has not been studied well to date. Though both of these radiation therapies have been used in the past to treat prostate cancer, there has never been a study that compares the effects of these two therapies to see which one has less side effects.
In this research study, we are comparing IMRT to PBT to determine which therapy best minimizes the side effects of treatment.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Radiation: Proton Beam Therapy Radiation: Intensity Modulated Radiation Therapy||Not Applicable|
Because no one knows which of the study options is best, you will be "randomized" into one of the study groups: IMRT or PBT. Randomization means that you are put into a group by chance, like flipping a coin. Neither you nor the research doctor will choose which group you will be in. You will have an equal chance of being placed in either group. Randomization makes the study better from a scientific point of view because it helps ensure that patients receiving IMRT and proton therapy are similar. You will be receiving only one type of radiation, either IMRT or PBT throughout your participation in the study.
Before you begin radiation therapy you will have a pelvic CT scan in order to design your radiation treatment. Doctors will use information gathered from these scans to plan the best way to deliver radiation to your tumor.
Both types of radiation therapy will be given once a day for 5 days (no weekends or holidays) for up to 9 weeks. Both IMRT and PBT will require that you lie on a table for less than 15 minutes to obtain your treatment.
During each visit you will be asked questions about your general health and specific questions about any problems that you might be having and any medications you might be taking. You will also undergo a physical exam and complete some quality of life questionnaires.
After your radiation therapy you will have follow up visits at 3,6,9,12,18,24,36,48 and 60 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||454 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Intermediate Risk Prostate Cancer|
|Actual Study Start Date :||July 25, 2012|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||December 2026|
Active Comparator: PBT
Proton Beam Therapy
Radiation: Proton Beam Therapy
5 days per week up to 9 weeks
Active Comparator: IMRT
Intensity Modulated Radiation Therapy
Radiation: Intensity Modulated Radiation Therapy
5 times per week up to 9 weeks
- Efficacy of PBT vs. IMRT [ Time Frame: 2 years ]Compare the reduction in mean EPIC bowel scores for men with low or low-intermediate risk PCa treated with PBT versus IMRT at 24 months following radiation (where higher scores represent better outcomes)
- Disease Specific Quality of Life [ Time Frame: 2 years ]Assess the effectiveness of PBT versus IMRT for men with low or low-intermediate risk PCa in terms of disease-specific quality of life as measured by patient-reported outcomes, perceptions of care and adverse events
- Cost Effectiveness of PBT vs. IMRT [ Time Frame: 2 years ]Assess the cost-effectiveness of PBT versus IMRT under current conditions and model future cost-effectiveness for alternative treatment delivery and cost scenarios
- Radiation Dose and Bowel, Urinary and Erectile Function [ Time Frame: 2 years ]Develop predictive models to examine the associations between selected metrics of individual radiation dose distributions and patient reported bowel, urinary and erectile function
- Identification and Evaluation Biomarkers of PCa Behavior [ Time Frame: 2 years ]Identify and evaluate biomarkers of prostate cancer behavior and response to radiotherapy
- Long Term Survival [ Time Frame: 10 years ]Assess longer-term rates of disease-specific and overall survival as well as development of late effects such as second cancers
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- Diagnosed with histologically confirmed adenocarcinoma of the prostate based on core-biopsy within 1 year of study entry from TRUS
- Clinical stages T1c to T2c
- PSA <20, within 6 months of study entry
- Participants who are currently receiving Dutasteride (or have received it within the last 90 days) or Finasteride (or have received it within the last 30 days) must have a PSA of ≤ 10
- Gleason score ≤6, 3 + 4 = 7, or 4 + 3 = 7
- ECOG Performance Status 0-1 as documented within 3 months prior to study entry
- Must have complete history and physical examination within 45 days of study entry and digital rectal examination of prostate within 180 days of study entry
- Prior surgery (not including TURP), cryosurgery, radiofrequency ablation, chemotherapy or radiation for PCa
- Prior or planned androgen deprivation or bilateral orchiectomy
- Distant metastases, or clinically or pathologically involved lymph nodes confirmed by a CT scan within 365 days of study entry
- Hip prosthesis, inflammatory bowel disease or connective tissue disorder such as active scleroderma or lupus
- Individuals with a history of other malignancies are ineligible unless 1) they have been disease-free for at least 5 years OR 2) are deemed by the investigator to be at low risk for recurrence of that malignancy with no plans for adjuvant systemic chemotherapy and/or radiation therapy and have received overall principal investigator approval.
- Individuals who have AIDS (CD4 < 200 or an AIDS-defining illness) or are HIV positive and not on HAART therapy are ineligible.
- Major medical or psychiatric illness
Individuals with any of the following conditions are excluded from this study:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months.
- Transmural myocardial infarction within the last 6 months.
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- History of Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects within the last 12 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01617161
|United States, Florida|
|University of Florida Health Proton Therapy Institute|
|Jacksonville, Florida, United States, 32206|
|United States, Illinois|
|Northwestern Medicine Chicago Proton Center|
|Chicago, Illinois, United States, 60190|
|United States, Maryland|
|University of Maryland Medical Center|
|College Park, Maryland, United States, 20742|
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Mass General/North Shore Cancer Center|
|Danvers, Massachusetts, United States, 01923|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|United States, Missouri|
|Saint Louis, Missouri, United States, 63110|
|United States, New Jersey|
|Rutgers Cancer Institute of New Jersey|
|New Brunswick, New Jersey, United States, 08903|
|Princeton ProCure Proton Therapy Center|
|Somerset, New Jersey, United States, 08873|
|United States, Ohio|
|University Hospital of Cleveland|
|Cleveland, Ohio, United States, 44106|
|United States, Pennsylvania|
|Hospital of the University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|United States, Tennessee|
|Provision Proton Therapy Center|
|Knoxville, Tennessee, United States, 37909|
|United States, Washington|
|University of Washington Medical Center|
|Seattle, Washington, United States, 98195|
|Principal Investigator:||Jason A Efstathiou, MD, DPhil||Massachusetts General Hospital|
|Principal Investigator:||Justin E Bekelman, MD||University of Pennsylvania|
|Responsible Party:||Jason Efstathiou, Principal Investigator, Massachusetts General Hospital|
|Other Study ID Numbers:||
|First Posted:||June 12, 2012 Key Record Dates|
|Last Update Posted:||August 24, 2022|
|Last Verified:||August 2022|
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male
Male Urogenital Diseases